Bruton Tyrosine Kinase Inhibitor-Based Therapy Versus Rituximab-Containing Regimens for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - Oct 10, 2026 - "BTK inhibitor-based therapy was associated with significantly longer PFS compared with rituximab-containing regimens, whereas the evidence for OS and ORR remained inconclusive. Very high heterogeneity indicates that the pooled PFS estimate represents an average across clinically distinct treatment questions rather than a uniform class effect, and treatment selection should remain individualized."
Journal • Retrospective data • Review • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Small Lymphocytic Lymphoma
|
|
Arshbeer Singh Sandhu; Haris Mumtaz Malik; Maham Fatima; Maryam Akhtar; Muhammad Awais Bin Abdul Malik; Sadia Yousaf; Sana Mansoor; Tayyab Mumtaz Khan; Uswah Ilyas
|